Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON30521
NL-OMON30521
Recruiting
Not Applicable

Risk factors for non-melanoma skin cancer (NMSC) 1. Skin carcinoma progression analyzed by genome-wide gene expression profiling and mimicked by validated organotypic in vitro human skin cancer models; towards an integrative system-biology approach and an in vitro screening method for targeted skin cancer therapies. 2.Genetic and environmental risk factors for the development of skin cancer in organ-transplant recipients. - Risk factors for non-melanoma skin cancer

eids Universitair Medisch Centrum0 sites1,500 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsskin cancersquamous cell carcinoma10040900

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
skin cancer
Sponsor
eids Universitair Medisch Centrum
Enrollment
1500
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Organ\-transplant patients and immunocompetent persons with and without skin cancer.

Exclusion Criteria

  • •No consent of the patient.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)Non-melanoma Skin Cancer
NCT03693937Sensus Healthcare776
Active, not recruiting
Phase 1
Risk of Skin Cancer on Skin Areas Treated with Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
EUCTR2012-003112-31-DEEO Pharma A/S480
Active, not recruiting
Phase 1
Risk of Skin Cancer on Skin Areas Treated with Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
EUCTR2012-003112-31-FREO Pharma A/S480
Active, not recruiting
Not Applicable
Risk of Skin Cancer on Skin Areas Treated with Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
EUCTR2012-003112-31-GBEO Pharma A/S480
Active, not recruiting
Not Applicable
Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive - PROSKIMedical condition: renal transplant-patients at high-risk for skin cancerTransplant recipients have a high risk to develop skin malignancies. This depends on the immunosuppressive drugs and is related to the dosage. This study assesses whether a switch to a SRL-immunosuppressive therapy decreases the incidence/reoccurence of skin neoplasm.
EUCTR2006-001528-38-DECharité Universitätsmedizin Berlin